Mortimer J, Livingston R B, Hardesty I J, Groppe C W, Purvis J D, Gupta M, Flournoy N
Cancer Treat Rep. 1984 Jul-Aug;68(7-8):1017-8.
Twenty-seven women with disseminated estrogen receptor-negative breast cancer received an aggressive chemotherapy program of prednisone, methotrexate, 5-FU, doxorubicin, and cyclophosphamide. Responses were achieved in 21 of 26 (81%) evaluable patients, eight (31%) of whom had complete responses. The median survival was 17 months. Despite the favorable overall response and a significant number of complete responses, all patients eventually relapsed. Although most patients relapsed systematically, two relapsed initially in the CNS.
27例雌激素受体阴性的播散性乳腺癌女性患者接受了泼尼松、甲氨蝶呤、5-氟尿嘧啶、阿霉素和环磷酰胺的积极化疗方案。26例可评估患者中有21例（81%）获得缓解，其中8例（31%）完全缓解。中位生存期为17个月。尽管总体缓解情况良好且有相当数量的完全缓解，但所有患者最终均复发。虽然大多数患者是系统性复发，但有2例最初在中枢神经系统复发。
